The Product Manufactory (TPM) offers professional design and engineering services for customers performing product development. The services side of TPM works on a contract basis and engages with customers to develop concepts and prototypes based on their specifications and requirements.
ANDalyze, Inc. was founded in 2005 to focus on catalytic DNA biosensor technology for detecting heavy metals, diverse analytes, and biological molecules. The technology was developed at the University of Illinois at Urbana-Champaign by Prof. Yi Lu. Professor Lu has developed a superior methodology for detecting and quantifying analyte levels based on the discovery of the catalytic property of DNA (DNAzymes). This technology is a universal platform that offers a simple, fast, inexpensive, and reliable detection of trace metals and other analytes.
The Personal Glucose Meter (PGM) is a widely available and proven medical device that is used by millions of diabetics around the globe. Today’s glucose meter is the culmination of over 30 years of engineering and development efforts to make it do one thing extraordinarily well: measure blood glucose levels anytime, anywhere. GlucoSentient has developed a powerful technology that is transforming the PGM into a device that is capable of quantitatively and conveniently detecting other non-glucose targets.
Serionix develops high performance, affordable technologies for water and air purification. Using fibrous activated carbon and ion-exchange materials, Serionix purification is differentiated by rapid rates of contaminant uptake, well-defined selectivity for targeted chemicals, and potential for low-cost production. Serionix aspires to contribute to local economic growth by developing and marketing or licensing technologies that improve people’s lives in an environmentally and socially responsible way.
Inprentus manufactures blazed diffraction gratings for x-ray and extreme ultraviolet light (EUV). Inprentus was founded in June 2012 by University of Illinois Urbana-Champaign physics professor Peter Abbamonte to commercialize an innovative, dual-atomic microscope scribing technology - a technique for carrying out nano-scale lithography via mechanical deformation of metallic surfaces. X-ray diffraction gratings are used by many academic institutions, government laboratories, and Fortune 500 companies at synchrotron radiation facilities for a variety of scientific and commercial applications.
HercuTech Inc. manufactures and markets HercuWall, a panelized concrete wall system that is used in lieu of concrete block wall and wood frame construction in new residential and commercial building structures. HercuWall is the product of years of engineering, development, and testing resulting in a building technology that exceeds concrete block wall construction in strength, performance and speed of installation. HercuWall affords owners hurricane zone ratings and energy efficiency, while benefiting contractors and developers with shorter construction cycles and scalability at a cost typically less than concrete block construction.
Innara Health is a commercial stage medical device company developing and selling pulsatile neurostimulation products that address the overwhelming problem of incompetent feeding in premature infants. Innara’s first product, the NTrainer™ System, solves this problem by assessing and treating their dysfunctional oral feeding, accelerating healthy development and enabling them to leave the hospital sooner.
Phi Optics Inc. offers an affordable light microscopy device with label-free, non-invasive, quantitative, nanoscale, 3D tomographic and real-time information capabilities all rolled into one, at a very attractive price point. As its initial product offering, Phi Optics is delivering a combination hardware-software platform that is a turn-key system inclusive of the industry-leading Zeiss microscope stand. The company was founded by world renowned scientist and author, Gabriel Popescu.
Diagnostic Photonics, Inc. is developing an intraoperative device that can be used for real-time assessment of breast cancer tumor margins based on the work of Dr. Stephen Boppart and Dr. Paul Scott Carney from the University of Illinois at Urbana-Champaign. Diagnostic Photonics’ device is rooted in Optical Coherence Tomography (OCT), a unique imaging modality that allows for non-invasive, cross sectional optical imaging in biological media with high resolution.
OceanComm has developed a high-speed wireless underwater modem which enables wireless video streaming underwater and wireless remote control of underwater vehicles. Currently, the oil and gas industry heavily relies on remotely operated vehicles (ROVs) to find and produce resources offshore. These vehicles are all tethered today, which results in significant operational costs. A wireless solution could eliminate the costs of having to tether an ROV.
Sabia, Inc. designs, manufactures, markets, sells and services PGNAA (prompt gamma neutron activation analysis) instrumentation systems that provide customers with process improvements based on real-time materials analyses. PGNAA provides an analysis of element composition of bulk materials and is heavily used in industries such as cement manufacture, coal mining, and minerals mining. SABIA offers a variety of services for companies that use any nuclear instruments, including nuclear source replenishment, maintenance of PGNAA analyzers, radiation surveys, commissioning and decommissioning gauges, leak tests and RSO services and training.
Adarza BioSystems, Inc. is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid. Founded in 2008, Adarza has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today. The Arrayed Imaging Reflectometry (AIR™) is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid. Adarza delivers industry leading precision, accuracy, and robustness enabling highly multiplexed protein detection with high sensitivity and specificity.
Kypha seeks to discover, develop and commercialize innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. The plan is for these tests to become standard of care, having application across a wide range of indications that include: lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Potential implications include earlier prediction of adverse events, optimizing treatment options, and overall better patient disease management.
ImmuVen, Inc. was acquired by a major pharmaceutical company in December, 2014. The company features a powerful, emerging life science technology -- high-affinity T cell receptors, a novel class of immune-targeting drugs and diagnostic agents.
Clarify Medical is a connected device that uses cutting edge LED technology to bring personal, private prescription phototherapy to patients with psoriasis, eczema and vitiligo. According to third party research, 95% of physicians would prescribe Clarify Medical because they could maintain a relationship with their patients.
Clarify brings handheld, guided therapy to millions of patients, while staying wirelessly connected to physicians and dermatologists. Clarify Medical improves care by bringing convenient, low-cost therapy into a patient’s home.
Cardea's focus is creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. Cardea is a biotech company based in San Diego, CA. Begun in late 2013, it is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products.
Medical Engineering Innovations, Inc. (MEI) is dedicated to the development and commercialization of electro-mechanical medical devices that provide better surgical tools to meet unmet needs, advance patient care, quality of life and healthcare cost effectiveness.
Metactive is developing novel, endovascular medical devices for the treatment of peripheral and neurovascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform.